Cashmere Karen A. 4

4 · ZyVersa Therapeutics, Inc. · Filed Dec 14, 2022

Form 4

Period: 2022-12-12

Chief Commercial Officer

Transactions

Award
Stock Options (right to buy)
2022-12-12+19,854→ 19,854 total
Exercise: $5.03Exp: 2027-10-30→ Common Stock (19,854 underlying)
Award
Stock Options (right to buy)
2022-12-12+9,927→ 9,927 total
Exercise: $5.03Exp: 2024-09-10→ Common Stock (9,927 underlying)
Award
Stock Options (right to buy)
2022-12-12+29,781→ 29,781 total
Exercise: $11.58Exp: 2029-04-02→ Common Stock (29,781 underlying)
Award
Stock Options (right to buy)
2022-12-12+21,840→ 21,840 total
Exercise: $16.36Exp: 2031-02-08→ Common Stock (21,840 underlying)
Award
Stock Options (right to buy)
2022-12-12+21,840→ 21,840 total
Exercise: $16.36Exp: 2032-01-28→ Common Stock (21,840 underlying)

Footnotes (5)

[F1]100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on September 10, 2014.
[F2]100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017.
[F3]100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.
[F4]The option vests in 3 equal annual installments commencing on February 8, 2022.
[F5]The option vests in 3 equal annual installments commencing on January 28, 2023.

Documents

1 file